Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q5VTD9
UPID:
GFI1B_HUMAN
Alternative names:
Growth factor independent protein 1B; Potential regulator of CDKN1A translocated in CML
Alternative UPACC:
Q5VTD9; O95270; Q5VTD8; Q6FHZ2; Q6T888
Background:
Zinc finger protein Gfi-1b, also known as Growth factor independent protein 1B, plays a pivotal role in the development and differentiation of erythroid and megakaryocytic lineages. It functions as a transcriptional regulator, influencing the expression of genes involved in hematopoietic differentiation and blood cell development. Gfi-1b's ability to bind to gamma-satellite DNA and auto-repress its expression showcases its complex regulatory mechanisms.
Therapeutic significance:
Gfi-1b's involvement in Bleeding disorder, platelet-type, 17, highlights its clinical relevance. This disorder, characterized by platelet dysfunction and abnormal bleeding, underscores the therapeutic potential of targeting Gfi-1b. Understanding the role of Gfi-1b could open doors to potential therapeutic strategies for managing bleeding disorders and improving platelet function.